The conversation around GLP-1 medications has shifted dramatically over the past few years. A topic once limited to medical clinics has now become one of the biggest trends in weight loss — and it’s no surprise why. These medications are producing results that lifestyle intervention alone rarely achieves, and patients who’ve struggled with obesity for years are finally seeing real movement on the scale.
But with all the noise around brand names, before-and-after posts, and conflicting advice online, the most common question we hear in the clinic isn’t “does it work?” It’s: how fast does it actually work, and what should I realistically expect?
It’s a fair question — and one that deserves a straight, experience-backed answer. Dr. Robert Fortino, widely known as the “Philly Diet Doc,” is a board-certified internal medicine physician with over 25 years of experience helping patients in Philadelphia and South Jersey take back control of their health.
He has spent decades addressing the root causes of chronic conditions — including obesity — through medically supervised, science-backed treatment. Together with his experienced team of nurse practitioners, Dr. Fortino brings the same level of personalized, results-driven care to every patient who walks through the door.
This blog answers that question — and every important one that comes before and after it.
Q: What exactly are GLP-1 weight loss injections, and how do they work in the body?
GLP-1 stands for glucagon-like peptide-1, a hormone your gut naturally produces in response to eating. It signals the brain that you’re full, slows gastric emptying so food moves through your stomach more gradually, and regulates insulin response. GLP-1 receptor agonist medications — like semaglutide injection for weight loss — mimic this hormone artificially, amplifying the body’s natural satiety signals at a level that food intake alone never achieves.
In practical terms: patients feel full sooner, stay full longer, and experience significantly fewer food cravings. The psychological battle of resisting food becomes physiologically easier. That’s not willpower — it’s biochemistry working in your favor. What makes these medications different from appetite suppressants of the past is that they work through a hormonal pathway that also supports blood sugar regulation and cardiovascular health — benefits that extend well beyond the number on the scale.
Q: How quickly do GLP-1 injections start working? When will I actually notice a difference?
This is the most important question to answer honestly, because unrealistic expectations from GLP-1 injections are the primary reason people abandon treatment too early.
Most patients begin to notice a reduction in appetite within the first one to two weeks — not dramatic weight loss, but a measurable change in how hungry they feel and how much they’re eating. Actual scale movement typically becomes visible between weeks four and eight, once the medication has been gradually titrated (increased in dose) and the body has adjusted.
Clinical data from real-world practice tells a clear story. A Mayo Clinic cohort study published in JAMA Network Open found that patients on semaglutide lost an average of 5.9% of total body weight at three months and 10.9% at six months. In the landmark STEP 1 clinical trial, participants achieved a mean body weight reduction of 14.9% over 68 weeks. The STEP 5 trial — the longest dedicated semaglutide obesity study to date — showed sustained weight loss of approximately 15% over 104 weeks (two full years).
The pattern is consistent: early weeks bring appetite changes and modest weight shifts; months two through six are where meaningful loss accelerates; and long-term use at therapeutic doses produces the most clinically significant results.
Q: Is tirzepatide different from semaglutide — and does one work faster or better?
Yes, they’re meaningfully different — and the clinical evidence now clearly distinguishes them.
Semaglutide is a GLP-1 receptor agonist. Tirzepatide weight loss treatment works as a dual agonist — it activates both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. That dual mechanism appears to produce superior results.
The SURMOUNT-5 trial — the first direct head-to-head comparison between these two medications, published in the New England Journal of Medicine — enrolled 751 adults with obesity or overweight without diabetes.
At 72 weeks, tirzepatide produced an average body weight reduction of 20.2%, compared to 13.7% with semaglutide. That’s a 47% greater relative weight loss. More than 31% of tirzepatide patients achieved a 25% or greater reduction in body weight — more than double the rate seen with semaglutide.
Neither medication produces results overnight. But for patients who are candidates for tirzepatide, the data supports it as the more potent option. A weight loss specialist doctor who reviews your full health history can help you understand which medication is appropriate for your specific situation.
Q: What does a realistic week-by-week timeline actually look like?
Understanding the arc of treatment helps patients stay committed during the early weeks when results are subtle. Here’s an honest, evidence-based progression:
Weeks 1–4: The starting dose is intentionally low to minimize gastrointestinal side effects. Appetite suppression begins, but the dose is not yet therapeutic for meaningful weight loss. Patients often report eating smaller portions without trying — that’s the medication working. Scale movement is minimal or absent at this stage, which is expected and normal.
Weeks 5–12: Dose escalation begins. Appetite reduction becomes more pronounced. Most patients begin seeing consistent weight loss of one to two pounds per week. Energy levels often improve as food-related cravings decrease and blood sugar stabilizes. This is also the phase where healthy swaps in diet become significantly easier to maintain — the medication reduces the psychological resistance that makes dietary change so hard without support.
Months 3–6: The most visibly productive phase for most patients. The combination of therapeutic dosing, improved dietary habits, and compounding weight loss creates noticeable physical changes. Patients managing obesity or high bp often report measurable improvements in blood pressure and metabolic markers during this window.
Months 6–12 and beyond: Continued loss at a slower pace as the body approaches a new equilibrium. Maintenance becomes the focus alongside continued weight reduction. The STEP 5 trial confirmed that two years of treatment produced sustained results — weight did not return while medication continued.
Q: What side effects should I expect, and how do patients typically manage them?
The most common side effects are gastrointestinal — nausea, mild bloating, and changes in bowel habits — and they’re almost universally associated with the early titration phase when the dose is being increased.
In the SURMOUNT-5 trial, gastrointestinal events causing patients to stop treatment occurred in 5.6% of the semaglutide group and 2.7% of the tirzepatide group — indicating that most patients tolerate these medications with appropriate medical guidance.
Practical management strategies that help:
Eating smaller portions and slowing down at meals reduces nausea significantly. The medication already suppresses appetite, so large meals create a collision with the slowed gastric emptying — smaller portions resolve it. Staying ahead on hydration is critical; many side effects complaints trace back to dehydration rather than the medication itself.
Sleep quality and duration also affect tolerance — poorly rested patients tend to experience more pronounced side effects and slower adaptation. Addressing sleep as part of the overall treatment plan isn’t optional; it’s clinical. This is especially relevant in the context of the broader weight gain epidemic, where disrupted sleep has become a compounding factor in metabolic dysfunction across the population.
Q: What other treatments complement GLP-1 injections for better results?
Several adjunctive therapies are increasingly used alongside GLP-1 medications in physician-supervised weight management programs.
Glutathione injections support cellular health, reduce oxidative stress, and are particularly relevant for patients who experience fatigue during the early phase of treatment. As the body adjusts to caloric reduction and metabolic changes, antioxidant support can meaningfully improve energy and recovery.
B12 shots address a common but often undetected deficiency that can cause fatigue, cognitive fog, and reduced exercise tolerance — all of which undermine the momentum that weight loss treatment is trying to build. B12 supplementation via injection bypasses the absorption issues that oral supplements don’t always resolve.
Skinny shots — a term used broadly for lipotropic injection combinations that may include B12, methionine, inositol, and choline — are used in some programs to support fat metabolism, liver function, and energy alongside primary weight loss treatment. Their role is supportive rather than primary, but patients often notice improved energy and recovery when incorporated appropriately.
For patients who are planning a significant life event and want to slim down before your wedding or a major milestone, these complementary therapies can help optimize the pace and quality of results during a defined window.
Ready to find out whether GLP-1 treatment is right for you? Call us @ 215.336.8000 (PA) and @ 856.318.4100 (NJ) to schedule a consultation with Dr. Robert Fortino — serving patients in Philadelphia, South Jersey, and surrounding areas.
